Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ First in-human, non-invasive femtosecond laser trabeculotomy data ➤ Special Protocol Assessment received for Phase 2b/3 trial for dry AMD treatment ➤ FDA gives clearance to IND for geographic atrophy treatment ➤ Positive preliminary data in trial for retinitis pigmentosa and Leber congenital amaurosis therapy ➤ Wet AMD treatment proceeds to Phase 2 trial ➤ ASCRS news and events
➤ FDA approves twice-daily use of presbyopia drop ➤ Study: drug approved for high blood pressure shows promise for blinding childhood disease ➤ Breakthrough device designation granted to investigational dry AMD therapy ➤ Positive topline results for Phase 2 study of retinitis pigmentosa treatment ➤ FDA approves pediatric enrollment in trial for retinitis pigmentosa and Leber congenital amaurosis ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication ➤ 24-month data on AMD photobiomodulation therapy ➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment ➤ Pre-IND meeting for treatment of corneal endothelial disease ➤ IND submitted for geographic atrophy treatment ➤ Second Phase 3 trial for dry eye disease therapy ➤ ASCRS news and events
➤ First FDA-approved treatment for geographic atrophy ➤ FDA accepts NDA for presbyopia drop ➤ NDA for geographic atrophy drug accepted with priority review ➤ Study: 5-year visual field data with MIGS device ➤ ASCRS news and events
➤ Clinical trial for new cataract surgery technology ➤ Topline results from Phase 2 trial investigating treatment for persistent corneal epithelial defect ➤ Update on sustained-release glaucoma implant and Glaukos cornea programs ➤ First patient enrolled in Phase 3 trial for presbyopia drop ➤ ASCRS news and events
➤ FDA approves NDA for IOP-lowering drug ➤ NDA submitted for presbyopia drop ➤ IND accepted for investigational treatment of persistent corneal epithelial defect ➤ Topline results from Phase 2 study of novel sedation drug for cataract surgery ➤ First patient enrolled in Phase 3 trial for investigational TED therapy ➤ Complimentary access to video journal ➤ ASCRS news and events
Following updates to prescribing information on pilocarpine 1.25% and release of the ASCRS Consensus Statement on the topic, several members of the ASCRS leadership sat down to discuss presbyopia-correcting drops. Sumit “Sam” Garg, MD, EyeWorld Chief Medical Editor, led a discussion with Elizabeth Yeu, MD, Cathleen McCabe, MD, and Douglas Rhee, MD. They addressed some of the reported adverse events, how to examine and speak to patients about the product, uses of pilocarpine in the glaucoma field, and more.
In August, the Prescribing Information for VUITY (pilocarpine) was updated following a voluntary submission by Allergan to the FDA. This ASCRS Task Force was convened to develop an understanding of the data and a preliminary consensus on appropriate counseling of patients regarding risks associated with the use of Vuity.
With recent case reports showing rare but serious adverse effects with the use of Vuity (pilocarpine, Allergan), EyeWorld spoke with Dagny Zhu, MD, to gain additional insights and perspectives. She commented on the adverse effects, her recommendations for counseling and prescribing, and an off-label use she has found for the product.
➤ FDA accepts NDA for ‘first-of-its-kind’ anti-inflammatory for dry eye ➤ Positive Phase 3 results for investigational presbyopia therapy ➤ Study: long-term visual outcomes with remote monitoring technology ➤ Companies partner to create tool to assess fall risk ➤ ASCRS news and events